Emplicure AB Year-end Report 2021 - Further pieces in place to deliver upon our promises in 2022
Fourth quarter, 1 October - 31 December 2021
· Net revenue totalled 0.0 (0.1) MSEK
· EBIT totalled -5.2 (-1.6) MSEK
· EBITDA totalled -5.1 (-1.6) MSEK
· Cash flow totalled -4.6 (+0.6) MSEK
· Earnings per share -0.25 (-0.14) SEK
Accumulated, 1 January - 31 December 2021
· Net revenue totalled 0.1 (0.6) MSEK
· EBIT totalled -16.7 (-4.6) MSEK
· EBITDA totalled -18.4 (-4.6) MSEK
· Cash flow totalled +18.8 (+2.5) MSEK
· Earnings per share -1.16 (-0.43) SEK
· Emplicure was listed on Nasdaq First North Growth Market
Adviser
Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via [email protected]
This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on February 22, 2022 at 08:30 CET.
For more information, please contact:
| Torbjörn W. Larsson | Erik Magnusson |
| CEO | CFO, Investor Relations |
| Tel: +46 (0)70 747 65 99 | Tel: +46 (0)70 856 52 45 |
| Email: [email protected] | Email: [email protected] |
Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com
Attached files
PM-Emplicure-AB-Year-end-Report-2021-Further-pieces-in-place.pdfEmplicure-AB-Year-end-Report-2021-Further-pieces-in-place.pdf
Om Emplicure
Emplicure utvecklar nya innovativa produkter baserat på kombinationen av redan godkända aktiva substanser och avancerad materialvetenskap inom biokeramer.
Prenumerera
Få löpande information från Emplicure via e-post.
